News and Trends 7 Oct 2022 Ziphius and UZ Ghent collaborating on manufacture of saRNA-based vaccines Ziphius Vaccines, a biopharmaceutical company developing vaccines and therapeutics based on self-amplifying RNA (saRNA), and UZ Ghent have entered a public-private collaboration for the scale up and manufacturing of prophylactic self-amplifying RNA vaccines based on GMP (good manufacturing practice) standards. The collaboration is a first in Europe where a university hospital produces GMP grade prophylactic […] October 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 Regen BioPharma files patent on new RNA/DNA-based approach to cancer immunotherapy Regen BioPharma, Inc. has filed a provisional patent application with the USPTO entitled “Dual Checkpoint Inhibitor Aptamer Based Therapeutics.” The application covers novel compositions of matter capable of acting as conventional checkpoint inhibitor drugs while simultaneously silencing genes that regulate T cells and cancer cells such as NR2F6 and Survivin. The company says this platform […] September 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Global consortium looks to develop breakthrough RNA-based anti-cancer immunotherapy The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, Israel, is to lead CanceRNA, a global consortium aiming to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses. While RNA-based therapies, namely mRNA vaccines, shone during the pandemic and saved millions of lives, they have yet to be successfully tested […] September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis SiSaf Ltd, an RNA delivery and therapeutics company, has announced positive data confirming safety and efficacy of its Bio-Courier next generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an effective non-viral delivery system for autosomal dominant osteopetrosis type 2 (ADO2) siRNA therapy. The data was presented at the American Society of Bone and Mineral Research […] September 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Benchling launches solution to boost mRNA and RNA therapeutics development Benchling has launched what it says is the industry’s first full set of capabilities for designing, modeling, and studying natural and chemically modified RNA in a single solution. As the biopharma industry increases its focus on developing RNA therapeutics, Benchling said its new RNA solution is the first purpose-built offering on the market to help […] September 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Gene therapies for lung cancer identified by international team of scientists Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered. CRISPR genome-editing is a powerful tool that gives scientists a cheap and easy way to find and alter a specific piece of DNA within a cell – the ‘cut and paste’ of the biological world. […] August 24, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2022 AUM LifeTech secures $400,000 grant for lung cancer immunotherapy program AUM LifeTech, Inc., a Philadelphia-based preclinical stage biotech company, has received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to advance its preclinical program in lung cancer immunotherapy using a non-viral RNA-targeting gene therapy approach. “This grant will help advance our preclinical immunotherapy […] August 17, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 siRNA company Eleven Therapeutics seals $22M funding Eleven Therapeutics has raised a total of $22 million in seed funding. Among the roster of funders is the Bill & Melinda Gates Foundation, which committed $9 million in funding to Eleven, including $5 million towards future equity investment supporting the development of a first-of-its-kind platform that designs small interfering RNAs (siRNAs) with ultra-long durability […] August 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 22 Jul 2022 The coming of age story of RNAi technology The first RNA interference (RNAi) therapy was approved in 2018, after 20 years in development. What can we expect to see in the RNAi field in the future? After two decades of scientific effort, multiple devastating clinical trial setbacks, and billions of dollars spent on research and development, RNAi therapies are finally establishing themselves in […] July 22, 2022 - 7 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 ICL and PlantArcBio look to use RNAi to boost crop yields ICL, a global specialty minerals company, and ag-biotech company PlantArcBio, Ltd., have announced the development of a novel bio-stimulant technology platform to improve crop yields while having a minimal impact on the environment. The platform uses RNAi (RNA interference) technology to maximize a plant’s natural yield increase mechanisms, without any genetic modification, and was the […] July 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2022 Study results reveal bleeding episodes are significantly reduced by hemophilia drug People suffering from a severe blood disorder may only have to take a once-monthly drug following successful results from an ongoing study. Global healthcare company, Sanofi, has been conducting a study into fitusiran prophylaxis and results have shown it reduces bleeds by 61 per cent in people with hemophilia A or B, with or without […] July 11, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Therorna funding to accelerate circRNA-based platform Therorna Inc., a Chinese biotech company specializing in the development of circular RNA (circRNA) technology-based new vaccines and therapies, including for COVID-19, has completed a $42 million series A financing round. The funding was co-led by MSA Capital, with participation from Sherpa Healthcare Partners, 3H Health Investment, and existing investors Quan Capital and Cenova Capital. […] June 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email